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Abstract
Background: Decision-makers may consider vaccinating girls and boys with different HPV vaccines to benefit from their
respective strengths; the quadrivalent (HPV4) prevents anogenital warts (AGW) whilst the bivalent (HPV2) may confer
greater cross-protection. We compared, to a girls-only vaccination program with HPV4, the impact of vaccinating: 1) both
genders with HPV4, and 2) boys with HPV4 and girls with HPV2.
Methods: We used an individual-based transmission-dynamic model of heterosexual HPV infection and diseases. Our base-
case scenario assumed lifelong efficacy of 100% against vaccine types, and 46,29,8,18,6% and 77,43,79,8,0% efficacy against
HPV-31,-33,-45,-52,-58 for HPV4 and HPV2, respectively.
Results: Assuming 70% vaccination coverage and lifelong cross-protection, vaccinating boys has little additional benefit on
AGW prevention, irrespective of the vaccine used for girls. Furthermore, using HPV4 for boys and HPV2 for girls produces
greater incremental reductions in SCC incidence than using HPV4 for both genders (12 vs 7 percentage points). At 50%
vaccination coverage, vaccinating boys produces incremental reductions in AGW of 17 percentage points if both genders
are vaccinated with HPV4, but increases female incidence by 16 percentage points if girls are switched to HPV2
(heterosexual male incidence is incrementally reduced by 24 percentage points in both scenarios). Higher incremental
reductions in SCC incidence are predicted when vaccinating boys with HPV4 and girls with HPV2 versus vaccinating both
genders with HPV4 (16 vs 12 percentage points). Results are sensitive to vaccination coverage and the relative duration of
protection of the vaccines.
Conclusion: Vaccinating girls with HPV2 and boys with HPV4 can optimize SCC prevention if HPV2 has higher/longer cross-
protection, but can increase AGW incidence if vaccination coverage is low among boys.
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Introduction
Infection with human papillomavirus (HPV) types is a necessary
cause of cervical cancer, with HPV-16/18 accounting for 70% of
these cancers. The other most frequent oncogenic HPV types
worldwide (HPV-31,-33,-45,-52, and -58) contribute to an
additional 20% of cervical cancers [1]. Infection with high
oncogenic risk types, mainly HPV-16, has also been associated
with other anogenital (vulvar, vaginal, anal, penile) and head and
neck cancers [2–4]. Infection with low oncogenic risk types, such
as HPV-6 and -11, is associated with anogenital warts (AGW) [5]
and recurrent respiratory papillomatoses [6]. Although it is well
recognized that HPV causes substantial burden of diseases in
women, the burden in men is also considerable [7]. The number
of non-cervical HPV-related cancers that occur each year is about
the same for men and women [7].
Two prophylactic HPV vaccines are currently licensed for use
in females in many countries: the bivalent and quadrivalent
vaccines that protect against types HPV-16/18 and HPV-16/18/
6/11, respectively. Given evidence that the HPV vaccines are
highly efficacious (vaccine efficacy against persistent infections and
cervical lesions (VE) = 98–100%) [8,9], and cost-effective in
preadolescent females [10], most developed countries have
introduced routine vaccination of girls. Many of these countries
use the quadrivalent vaccine (e.g., the U.S., U.K., Canada and
Australia) [11–14].
A randomized clinical trial has shown the HPV quadrivalent
vaccine to be safe and efficacious against persistent infections
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(VE=86%) and external genital lesions (VE= 90%) in young
males, and against precancerous anal lesions in men-who-have-
sex-with-men (MSM) (VE=78%) [15,16]. Following these results,
the quadrivalent vaccine has been licensed for use in males in
several countries [11,17,18]. However, only a few countries,
including the U.S. and Australia, have introduced male/female
HPV immunization programs using the quadrivalent vaccine. In
many countries, the main barrier for vaccinating boys is cost-
effectiveness. Most studies suggest that vaccinating boys in
addition to girls is unlikely to be cost-effective if vaccination
uptake is high among girls (i.e. .50%), due to herd immunity
effects [19–25].
Policy makers examining male/female vaccination programs
may consider vaccinating girls and boys with different vaccines to
benefit from their respective potential strengths and differential
costs. This option has been examined in Quebec, Canada.
Evidence suggest that the quadrivalent vaccine prevents AGW in
both females and males (herd immunity) following girl-only
vaccination programs [26–28]. On the other hand, the bivalent
vaccine may confer greater cross-protection against high onco-
genic risk HPV-types 31/33/45/52/58 [29] and/or longer
duration of protection against the vaccine HPV-types 16/18
[30]. Therefore, using the bivalent vaccine for girls and the
quadrivalent for boys could potentially increase the population-
level effectiveness against cervical lesions and cancer without
significantly impacting the effectiveness against AGW (because of
herd immunity from vaccinated boys). Hence, using the bivalent
and quadrivalent HPV vaccines could represent an opportunity to
share the potential advantages and uncertainties of the vaccines
described above.
The objective of this study is to examine and compare the
potential incremental impact of two male/female HPV vaccina-
tion strategies (versus girls-only quadrivalent vaccination): 1)
vaccinating both genders with the quadrivalent vaccine, and 2)
vaccinating boys with the quadrivalent vaccine and switching girls
to the bivalent vaccine.
Methods
We developed HPV-ADVISE (Agent-based Dynamic model for
VaccInation and Screening Evaluation), an individual-based
transmission-dynamic model of partnership formation and disso-
lution, and natural history of multi-type HPV infection and disease
[31,32]. Individuals in the model are attributed three risk factors
for HPV infection and disease: gender, a level of sexual activity
(Low=L0 to High=L3) and a screening behaviour (No screen-
ing = S0 to High screening frequency = S4). Eighteen HPV-types
are modeled individually, including the vaccine and cross-
protective types. It is assumed that the natural history (e.g.,
transmission, persistence, disease progression) of a specific HPV-
type is independent of co-infections within an individual. The
HPV diseases included in the model are AGW, cervical cancer,
and cancers of the vulva, vagina, penis, anus, and oropharynx.
Vaccine efficacy is type-specific and can be applied to any of the
18 HPV-types included in the model. Each vaccinated individual
is given a specific duration of protection against the vaccine types
sampled from a normal distribution. Cytology-based cervical
cancer screening, which prevails in Canada, was assumed for the
models. Screening rates are a function of a woman’s screening
behaviour level, previous screening test results, and age.
The sexual behaviour, natural history and cervical screening
parameters were identified through calibration (see Van de Velde
et al. [32] and http://www.marc-brisson.net/HPVadvise.pdf for
methods, parameter values and model fit). We identified 10
parameter sets (out of 285,000) that fit simultaneously 639 pre-
specified sexual behaviour, HPV epidemiology and screening data
targets [33–45]. Variability surrounding model predictions is
presented as the median, 10th and 90th percentiles of results from
the posterior parameter sets, referred to as the 80 percent range
(80%R).
In our base case, we assumed that vaccine efficacy against HPV-
vaccine types is 100%, vaccine efficacies against non-vaccine HPV-
types are the published type-specific efficacies against persistent
infection [29], and vaccine protection (including cross-protection) is
lifelong.A lifelongprotectionwaschosen forourbasecase to illustrate
the maximum difference that could be obtained from the two
vaccination strategies. However, analysis using shorter durations of
protection (20 years for vaccine-types and 10 years for cross-
protection [29,46,47]) were performed to examine the sensitivity of
results to thisuncertainty.Sensitivity analyseswerealsoperformedby
varying vaccination coverage and cross-protective efficacy. Vacci-
nation coverage was varied to represent the situation in different
countries (e.g. coverage,50% in theU.S. and.70% inAustralia or
Canada). We also examined scenarios where the vaccination
coverage of boys was lower than in girls, to represent results from
acceptability studies of boys’ vaccination among parents [48,49] and
we varied cross-protective efficacy by using different estimates
available in the literature [29] (Table S1).
Results
High Vaccination Coverage of Girls
Anogenital warts. Under base assumptions, the model
predicts that vaccinating 70% of 12-year-old girls with the
quadrivalent vaccine will produce a rapid decrease in the overall
incidence of AGW (Figure 1a–b). At equilibrium (70 years post-
vaccination), the incidence of AGW is estimated to be reduced by
84% (80%R:79,85) in females and 84% (80%R:76,85) in
heterosexual males. Adding the vaccination of 70% of 12-year-
old boys with the quadrivalent vaccine is expected to produce very
small incremental reductions in the incidence of AGW, irrespec-
tive of whether the girls are switched to the bivalent or remain with
the quadrivalent vaccine (Figures 1a–b–c).
In a male/female program, base case results are sensitive to the
vaccination coverage achievable among boys. If boys have a lower
vaccination coverage than girls (girls:70%, boys:50%), and girls are
switched to the bivalent vaccine, the model predicts that the
equilibrium incidence of AGW will be 31 percentage points higher
(80%R:24,39) in females and 19 percentage points higher
(80%R:16,22) in heterosexual males compared to girls-only
quadrivalent vaccination (Figures 1a–b). This is because the
effective population-level coverage against HPV-6/11 would be
reduced from about 35% (girls:70%, boys: 0%) to 25% (girls:0%,
boys:50%). Obviously, if both genders are vaccinated with the
quadrivalent, high population-level effectiveness against AGW
incidence will be maintained even if boys have lower vaccination
coverage (Figures 1a–b–c). Under this scenario, the effective
coverage against HPV-6/11 would increase from 35% (girls:70%,
boys = 0%) when vaccinating girls only to 60% (girls:70%,
boys:50%) when vaccinating both genders.
Because the potential to achieve significant gains fromvaccinating
boys depends on the population-level effectiveness of girls-only
vaccination, the incremental benefits of vaccinating boys is partic-
ularly sensitive to duration of vaccine protection. When assuming
limited duration of protection (20 years) and high coverage (boys &
girls = 70%), vaccinating boys in addition to girls with the quadriva-
lent vaccine produces larger incremental benefits in AGW incidence
reductionthanwhenassuming lifelongprotection (percentagepoints:
Using Different HPV Vaccines for Boys and Girls
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14 vs. 1 for females and 19 vs. 1 for heterosexual males-Figures 1c).
However, when assuming limited duration of protection (20 years),
switching girls to the bivalent vaccine leads to important losses in
population-level effectiveness against AGW compared to girls-only
quadrivalentvaccination (percentagepoints:220for femalesand25
forheterosexualmales-Figure1c).This isbecause, if vaccineduration
is shorter, vaccinating only boys against HPV-6/11 does not induce
the herd effects necessary to counter balance the loss of protection
caused by switching girls to a bivalent vaccine. In other words,
vaccinating 50% of boys only against HPV-6/11 produces smaller
herd immunity effects than vaccinating 50% of girls only. These
results suggest that vaccinating boys does not produce the same level
of herd immunity to girls than vice versa. This is most likely because
females have male partners that are generally older than them, and
the average duration of infection is longer for females.
Cervical intraepithelial neoplasia and cancer. Under
base assumptions, the model predicts that vaccinating 70% of
12-years-old girls with the quadrivalent vaccine will reduce the
incidence of diagnosed CIN2/3 and SCC by 59% (80%R:53,68)
and 66% (80%R:54,72) at equilibrium, respectively (Figures 2a–b).
Adding the vaccination of boys with the quadrivalent vaccine
(70% vaccination coverage) is expected to produce incremental
reductions in CIN2/3 and SCC incidence of 9 (80%R:7,10) and 7
percentage points (80%R:5,11), respectively (Figures 2a–b–c–d).
On the other hand, vaccinating boys and switching girls to the
bivalent vaccine (70% vaccination coverage for both genders)
produces greater incremental reductions in CIN2/3 (13 percent-
age points, 80%R:10,15) and SCC incidence (12 percentage
points, 80%R:8,14) than using the quadrivalent vaccine for both
genders (Figures 2a–b–c–d). These greater incremental reductions
in cervical disease are attributable to the higher cross-protective
efficacy of the bivalent vaccine and the assumption that cross-
protection is lifelong.
The difference in incremental benefit in cervical disease
prevention between the two male/female vaccination strategies
is highly sensitive to vaccine duration and cross-protective vaccine
efficacy (Figures 2c–d). When assuming shorter duration of
vaccine protection, the incremental benefit of vaccinating boys is
limited and the two male/female strategies result in similar
incremental gains (Figures 2c–d). This is because, when vaccine
duration is limited 1) vaccinating boys does not produce sufficient
herd immunity to further reduce CIN2/3 and SCC incidence
among females, and 2) cross-protection is too short to produce
incremental benefits for the bivalent compared to the quadrivalent
Figure 1. Estimated population-level impact of vaccinating 70% of 12-year-old girls and implementing boys’ vaccination on the
incidence of anogential warts. Percentage change following vaccination in a) females and b) males under base assumptions, and c) sensitivity
analyses varying vaccine duration and cross-protection. VDx= Vaccine Duration for cross-protective types; VDvac= Vaccine Duration for vaccine
types, VEvac =Vaccine Efficacy against vaccine types. Base case: Same characteristics Quad/Bi: VDx= VDvac = lifetime, VEvac = 100%. Sensitivity
analyses: Different characteristics Quad/Bi: Quad: VDvac = 20 yrs, VDx= 0 yr, VEvac = 100%; Bi: VDvac= VDx= lifetime, VEvac = 100%. Changes in
vaccination strategy occurred 5 years after the beginning of girls-only vaccination. Population of 170,000 individuals. Each parameter set was run 25
times. * the numbers at the top of the boxes represent percentage point changes in the magnitude of the reduction attributable to vaccination. With
lifelong duration of the vaccine, HPV6-11 AGW among females and males are eliminated in 45%, 35% and 100% of scenarios when girls only, boys
only or both genders are vaccinated with the quadrivalent vaccine (70% coverage). With shorter duration of the vaccine, HPV6-11 AGW are eliminated
in 0%, 0%, and 40% of scenarios when girls only, boys only or both genders are vaccinated with the quadrivalent vaccine (70% coverage).
doi:10.1371/journal.pone.0067072.g001
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vaccine. On the other hand, when assuming greater cross-
protection and/or longer duration of protection for the bivalent
vaccine, the incremental benefits of vaccinating boys with the
quadrivalent and girls with the bivalent are much higher than
vaccinating both genders with the quadrivalent vaccine.
Low Vaccination Coverage of Girls
Anogenital warts. Under base assumptions, the model
predicts that vaccinating 50% of 12-year-old girls with the
quadrivalent vaccine will reduce AGW incidence by 66%
(80%R:61,74) in females and 59% (80%R:52,71) in heterosexuals
males at equilibrium (Figures 3a–b). Vaccinating 50% of 12-year-
old boys with the quadrivalent vaccine, in addition to girls, is
expected to produce incremental reductions in AGW incidence of
17 percentage points (80%R:11,21) in females and 24 percentage
points (80%R:14,29) in heterosexual males (Figure 3a–b–c).
Conversely, vaccinating boys with the quadrivalent vaccine (50%
vaccination coverage) and switching girls to the bivalent vaccine is
expected to produce an increase of 16 percentage points
(80%R:7,21) in AGW incidence in females whilst maintaining
similar level of effectiveness in heterosexual males than the girls-
only strategy (Figure 3a–b–c).
If vaccination coverage among boys with the quadrivalent
vaccine reaches only 30% and girls are switched to the bivalent
vaccine, important increases in the incidence of AGW are
expected among both females (36 percentage points,80%R:23,42)
and heterosexual males (16 percentage points, 80%R:7,25) (versus
girls-only quadrivalent vaccination with 50% vaccination cover-
age) (Figures 3a–b). In contrast to high coverage, at low
vaccination coverage, the duration of vaccine protection has little
influence on differences in the incremental gains and losses of the
two male/female strategies (Figure 3c).
Cervical Intraepithelial Neoplasia and Cancer
Under base assumptions, the model predicts that vaccinating
50% of 12-years-old girls with the quadrivalent vaccine will reduce
the incidence of diagnosed CIN2/3 and SCC by 47%
(80%R:41,51) and 53% (80%R:44,56) at equilibrium, respectively
(Figures 4a–b). Vaccinating 50% of boys, in addition to girls, with
the quadrivalent vaccine is predicted to produce incremental
reductions in CIN2/3 and SCC of 12 percentage points
(80%R:8,15) and 12 percentage points (80%R:5,16), respectively
(Figures 4a–b–c–d). Given the higher bivalent cross-protection,
slightly higher incremental reductions in CIN2/3 (15 percentage
points, 80%R:12,18) and SCC (16 percentage points,80%R:8,21)
Figure 2. Estimated population-level impact of vaccinating 70% of 12-year-old girls and implementing boys’ vaccination on the
incidence of cervical disease. Percentage change following vaccination in the incidence of a) diagnosed cervical intraepithelial neoplasia 2 or 3
(CIN2/3) and b) squamous cell carcinoma (SCC) under base case and impact of sensitivity analyses varying vaccine duration and cross-protection on
incidence of c) CIN2/3 and d) SCC. VDx= Vaccine Duration for cross-protective types; VDvac = Vaccine Duration for vaccine types, VEvac =Vaccine
Efficacy against vaccine types, VEx = Vaccine Efficacy against cross-protective types. Base case: Same characteristics Quad/Bi: VDx=VDvac = lifetime,
VEvac = 100%, VEx =persistent infection (Table S1). Sensitivity analyses: Different characteristics Quad/Bi: Quad: VDvac = 20 yrs, VDx= 0 yr,
VEvac = 100% VEx= 0%; Bi: VDvac= VDx= lifetime, VEvac = 100%, VEx = CIN2+ (Table S1). Changes in vaccination strategy occurred 5 years after the
beginning of girls-only vaccination. Population of 170,000 individuals. Each parameter set was run 25 times. * the numbers at the top of the boxes
represent percentage point changes in the magnitude of the reduction attributable to vaccination. None of the scenarios eliminated CIN2/3 and SCC.
doi:10.1371/journal.pone.0067072.g002
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incidence are predicted when vaccinating 50% of boys with the
quadrivalent vaccine and switching girls to the bivalent vaccine
(Figures 4a–b–c–d).
The incremental reductions in CIN2/3 and SCC incidence
expected with these male/female vaccination strategies are highly
sensitive to vaccine duration and efficacy against cross-protective
HPV types (Figure 4c–d). Similarly to scenarios with high
vaccination coverage, the two strategies result in very similar
incremental reductions in CIN2/3 and SCC incidence if vaccine
duration is short (vaccine-type duration= 20 years, cross-protec-
tion= 10 years). On the other hand, if the bivalent is assumed to
have greater cross-protection and longer duration of protection,
switching girls to the bivalent vaccine and vaccinating boys with
the quadrivalent is predicted to be the optimal male/female
strategy in terms of incremental population-level effectiveness
against cervical lesions and cancer (Figure 4c–d).
Discussion
Our modeling analysis indicates that, at high vaccination
coverage of girls ($70%), adding boys to girls-only quadrivalent
vaccination programs will produce very small incremental
reductions in AGW incidence. On the other hand, at low
vaccination coverage of girls (#50%), a male/female strategy
can substantially improve the prevention of AGW for both,
females and males. Both strategies (vaccinating both genders with
the quadrivalent vaccine or vaccinating boys with the quadrivalent
vaccine and switching girls to the bivalent vaccine) are likely to
improve the population-level effectiveness of HPV vaccination
against cervical lesions and cancer. Vaccinating girls with the
bivalent while vaccinating boys with the quadrivalent vaccine may
optimize cervical lesions and cancer prevention, if duration of
cross-protection is long. However, to be more broadly successful,
this strategy requires achieving sufficiently high coverage of boys
with the quadrivalent vaccine to maintain AGW protection among
girls through herd immunity. Conversely, if duration of cross-
protection is limited, both male/female strategies result in similar
incremental effectiveness against cervical lesions and cancers.
If a male/female HPV immunization is implemented, vacci-
nating girls with the bivalent vaccine and boys with the
quadrivalent vaccine could maximize the prevention of cervical
lesions and cancers. However, many important uncertainties
Figure 3. Estimated population-level impact of vaccinating 50% of 12-year-old girls and implementing boys’ vaccination on the
incidence of anogential warts. Percentage change following vaccination in a) females and b) males under base assumptions, and c) sensitivity
analyses varying vaccine duration and cross-protection. VDx= Vaccine Duration for cross-protective types; VDvac= Vaccine Duration for vaccine
types, VEvac =Vaccine Efficacy against vaccine types. Base case: Same characteristics Quad/Bi: VDx= VDvac = lifetime, VEvac = 100%. Sensitivity
analyses: Different characteristics Quad/Bi: Quad: VDvac = 20 yrs, VDx= 0 yr, VEvac = 100%; Bi: VDvac= VDx= lifetime, VEvac = 100%. Changes in
vaccination strategy occurred 5 years after the beginning of girls-only vaccination. Population of 170,000 individuals. Each parameter set was run 25
times. * the numbers at the top of the boxes represent percentage point changes in the magnitude of the reduction attributable to vaccination. With
lifelong duration of the vaccine, HPV6-11 AGW among females and males are eliminated in 0%, 0% and 70% of scenarios when girls only, boys only or
both genders are vaccinated with the quadrivalent vaccine (50% coverage). With shorter duration of the vaccine, none of the scenarios eliminated
HPV6-11 AGW (50% coverage).
doi:10.1371/journal.pone.0067072.g003
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remain which could threaten the potential benefits of this strategy.
Firstly, this strategy requires high vaccination coverage among
boys to maintain the level of AGW prevention among girls.
However, studies indicate that vaccination coverage may be lower
for boys than girls [48,49]. For example, 67% of mothers intended
to have their daughter vaccinated compared to 39% for their son
[49] and a preference to vaccinate females over males was
observed in several studies [48]. Secondly, our results and those of
others [50] suggest that vaccinating boys produces lower levels of
herd immunity compared to vaccinating girls. This is most likely
because girls have older sexual partners and longer durations of
HPV infection [50]. For example when assuming 20 years of
protection against HPV-6/11, our model predicts that vaccinating
70% of girls with the quadrivalent will reduce AGW incidence by
63% among heterosexual males, through herd immunity. How-
ever, vaccinating 70% of boys will reduce AGW incidence among
females by only 47% through herd immunity (Figure 1c). These
observations suggest that, even at high coverage, girls could
experience substantial rebound in AGW incidence if they are
switched to the bivalent vaccine and duration of protection is
short. Thirdly, the additional benefit in the prevention of cervical
lesions and cancer using the bivalent vaccine (versus the
quadrivalent) is highly dependent on the duration of cross-
protection. The bivalent vaccine has been shown to be more
efficacious against HPV-31/33/45 related infection and cervical
lesions, but this efficacy may wane with time [29]. If these
preliminary observations are confirmed in future trials, the benefits
of switching girls to the bivalent vaccine would be limited.
Additional important drawbacks of having two different vaccines
are logistical and political. First, having different vaccines for girls
and boys can be a logistical challenge, and ultimately could incur
greater costs than a one-vaccine strategy. Secondly, depending on
public opinion and parental beliefs, having a vaccine that has
different properties for girls and boys can lead to discontent with
parents of children of one sex (e.g., girls) asking for the vaccine
given to the other sex to receive its additional benefits (e.g.,
quadrivalent for AGW protection).
This is the first study to assess the population-level impact of
male/female vaccination with different HPV vaccines for girls and
boys. Our results are similar to those examining the incremental
benefit of vaccinating boys using the quadrivalent for both
genders. Studies have shown limited incremental benefits of
vaccinating both genders with the quadrivalent vaccine compared
to girls-only vaccination programs [25,50], and cost-effectiveness
Figure 4. Estimated population-level impact of vaccinating 50% of 12-year-old girls and implementing boys’ vaccination on the
incidence of cervical disease. Percentage change following vaccination in the incidence of a) diagnosed cervical intraepithelial neoplasia 2 or 3
(CIN2/3) and b) squamous cell carcinoma (SCC) under base case and impact of sensitivity analyses varying vaccine duration and cross-protection on
incidence of c) CIN2/3 and d) SCC. VDx= Vaccine Duration for cross-protective types; VDvac = Vaccine Duration for vaccine types, VEvac =Vaccine
Efficacy against vaccine types, VEx = Vaccine Efficacy against cross-protective types. Base case: Same characteristics Quad/Bi: VDx=VDvac = lifetime,
VEvac = 100%, VEx =persistent infection (Table S1). Sensitivity analyses: Different characteristics Quad/Bi: Quad: VDvac = 20 yrs, VDx= 0 yr,
VEvac = 100% VEx= 0%; Bi: VDvac= VDx= lifetime, VEvac = 100%, VEx = CIN2+ (Table S1). Changes in vaccination strategy occurred 5 years after the
beginning of girls-only vaccination. Population of 170,000 individuals. Each parameter set was run 25 times. * the numbers at the top of the boxes
represent percentage point changes in the magnitude of the reduction attributable to vaccination. None of the scenarios eliminated CIN2/3 and SCC.
doi:10.1371/journal.pone.0067072.g004
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studies have consistently reported that this strategy was unlikely to
be cost-effective, at high vaccination coverage of girls due to herd
immunity [19–24]. Evidence suggest that herd immunity could
have occurred in Australia and the U.S., where AGW incidence
declined in females and heterosexual males [26–28,51] shortly
after the introduction of girls-only vaccination programs. Studies
have also shown that substantial incremental benefits can be
achieved by vaccinating boys when coverage in girls is low
[19,23,25,50,52]. The cost-effectiveness of vaccination programs
using different HPV vaccines for girls and boys has yet to be
examined. Based on these results, the cost-effectiveness will depend
on the relative durations of protection of the HPV vaccines, and
on whether the vaccination coverage of boys will be high enough
to maintain the effectiveness of girls-only vaccination against
AGW (in addition to the cost of the vaccines).
The following considerations should be taken into account when
interpreting our results. Firstly, only heterosexual transmission was
included in our HPV model. Given that the probability of
transmission of HPV is high and that the population of men-who-
have-sex-with-men (MSM) is estimated to be small (3–5% in the
U.S, Australia and Canada) [33,53,54], MSM are unlikely to
influence overall HPV transmission at the population-level.
Furthermore, although the inclusion of MSM could have slightly
increased the benefits of vaccinating boys, it is very unlikely that
their inclusion would change our conclusions. Secondly, we
purposely decided not to present the incremental effectiveness of
the two male/female strategies on the other HPV-related cancers.
We have previously shown that there is very little difference
between the two HPV vaccines in the population-level effective-
ness against these cancers since HPV-16/18 is found in more than
90% of these HPV-positive cancers [31,32]. Consequently, the
incremental benefits of the two strategies will be very similar.
Thirdly, although we performed a systematic literature review to
identify the most comparable estimates of cross-protection for the
two HPV vaccines [29], these estimates were derived from clinical
trials with different populations and designs [8,55,56], which could
partly explain difference in cross-protection between the two
vaccines.
The decision to include boys in HPV vaccination programs in
the U.S and Australia were partly based on cost-effectiveness [57].
In the U.S, where vaccination coverage is low (44% for at least one
dose), adding the vaccination of boys could increase the prevention
of HPV-related diseases and be cost-effective. On the other hand,
in Australia, where the vaccination coverage of girls is .70%,
reduction in vaccine price is thought to have played a determining
role in their recommendations. Policy makers in these countries,
and others examining whether to include boys in HPV vaccination
programs, may now consider using different vaccines for boys and
girls to benefit from their respective strengths and share
uncertainties/risks between the two genders. Future studies should
investigate the cost-effectiveness and acceptability of switching girls
to the bivalent vaccine within a male/female program, particularly
when considering the risk of reducing the prevention of AGW for
both, men and women. In conclusion, vaccinating girls with the
bivalent vaccine and boys with the quadrivalent vaccine may
optimize population-level effectiveness of HPV vaccination -
especially against cancers– under very specific conditions and
could increase the burden of AGW under a wide range of realistic
scenarios. Given uncertainties/risks regarding the vaccination
coverage that can be achieved in boys and the duration of cross-
protection of the bivalent vaccine, this strategy should be
considered only if vaccination coverage reaches high enough
levels in boys to maintain the gains in AGW prevention.
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